Last reviewed · How we verify
Salmeterol/Fluticasone propionate combination product
Salmeterol/Fluticasone propionate combination product is a Long-acting beta2-adrenergic receptor agonist/inhaled corticosteroid combination Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Maintenance and control of asthma symptoms, Maintenance and control of symptoms in patients with COPD.
Salmeterol/Fluticasone propionate combination product is a long-acting beta2-adrenergic receptor agonist/inhaled corticosteroid combination that works by relaxing airway muscles and reducing inflammation in the lungs.
Salmeterol/Fluticasone propionate combination product is a long-acting beta2-adrenergic receptor agonist/inhaled corticosteroid combination that works by relaxing airway muscles and reducing inflammation in the lungs. Used for Maintenance and control of asthma symptoms, Maintenance and control of symptoms in patients with COPD.
At a glance
| Generic name | Salmeterol/Fluticasone propionate combination product |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Long-acting beta2-adrenergic receptor agonist/inhaled corticosteroid combination |
| Target | Beta2-adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Salmeterol is a long-acting beta2-adrenergic receptor agonist that helps to relax airway muscles and improve breathing in patients with asthma and COPD. Fluticasone propionate is an inhaled corticosteroid that reduces inflammation in the lungs, making it easier to breathe. The combination of these two medications provides long-lasting relief from asthma and COPD symptoms.
Approved indications
- Maintenance and control of asthma symptoms
- Maintenance and control of symptoms in patients with COPD
Common side effects
- Headache
- Cough
- Oral thrush
- Bronchitis
- Sinusitis
Key clinical trials
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. (PHASE3)
- Advair HFA in Healthy and HAPE Predisposed Subjects (PHASE1, PHASE2)
- Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation (PHASE3)
- Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD (NA)
- A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients with Asthma (PHASE3)
- Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1) (PHASE3)
- Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Salmeterol/Fluticasone propionate combination product CI brief — competitive landscape report
- Salmeterol/Fluticasone propionate combination product updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Salmeterol/Fluticasone propionate combination product
What is Salmeterol/Fluticasone propionate combination product?
How does Salmeterol/Fluticasone propionate combination product work?
What is Salmeterol/Fluticasone propionate combination product used for?
Who makes Salmeterol/Fluticasone propionate combination product?
What drug class is Salmeterol/Fluticasone propionate combination product in?
What development phase is Salmeterol/Fluticasone propionate combination product in?
What are the side effects of Salmeterol/Fluticasone propionate combination product?
What does Salmeterol/Fluticasone propionate combination product target?
Related
- Drug class: All Long-acting beta2-adrenergic receptor agonist/inhaled corticosteroid combination drugs
- Target: All drugs targeting Beta2-adrenergic receptor
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Maintenance and control of asthma symptoms
- Indication: Drugs for Maintenance and control of symptoms in patients with COPD
- Compare: Salmeterol/Fluticasone propionate combination product vs similar drugs
- Pricing: Salmeterol/Fluticasone propionate combination product cost, discount & access